Smith+Nephew extends Advanced Wound Bioactives portfolio with US launch of CENTRIO Platelet-Rich-Plasma System

Core Insights - Smith+Nephew has launched the CENTRIO Platelet-Rich-Plasma (PRP) System, which is designed to assist in the natural healing process by maintaining a moist wound environment [1][3] - The CENTRIO PRP System is effective for managing chronic exuding wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers, and has received CMS coverage for diabetic patients [3][4] - The system is intended for point-of-care use in hospitals and physician offices, allowing customization based on the wound's shape, depth, and stage [3][4] Product Details - The CENTRIO PRP System is derived from a patient's own platelets and plasma, demonstrating efficacy in two randomized controlled clinical trials [3] - The product will be showcased at the Symposium on Advanced Wound Care (SAWC) Fall Conference in Las Vegas from September 3-6 [4] - Smith+Nephew has entered into an exclusive private label distribution agreement with Nuo Therapeutics Inc. to market the CENTRIO PRP System in the United States [5] Company Overview - Smith+Nephew is a global medical technology company focused on the repair, regeneration, and replacement of soft and hard tissue, with a mission to restore people's bodies and self-belief [7] - The company operates in approximately 100 countries and generated annual sales of $5.8 billion in 2024 [8] - Smith+Nephew is a constituent of the FTSE100 and employs around 17,000 people [8]